Pharmala Biotech Holdings Inc. (MDXXF)
| Market Cap | 18.55M +84.6% |
| Revenue (ttm) | 919.56K +201.2% |
| Net Income | -1.17M |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,000 |
| Open | 0.1765 |
| Previous Close | 0.1686 |
| Day's Range | 0.1569 - 0.1783 |
| 52-Week Range | 0.0614 - 0.2000 |
| Beta | 0.75 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 23, 2026 |
About Pharmala Biotech Holdings
Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada. [Read more]
Financial Performance
In fiscal year 2025, Pharmala Biotech Holdings's revenue was 605,498, a decrease of -41.51% compared to the previous year's 1.04 million. Losses were -2.18 million, 164.1% more than in 2024.
Financial numbers in CAD Financial StatementsNews
Water Tower Research Publishes Initiation of Coverage Report on PharmAla Biotech Holdings, Inc., "Monetizing Regulatory Advantage Through IP and Data"
August 27, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on PharmAla Biotech Holdings, Inc. (CSE:MDMA/OTC:MDXXF) titled, “...
PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner
U.S. Patent 12,679,817, covering novel processes for preparing the (R)- and (S)-enantiomers of MDMA and MBDB, granted to PharmAla by the US Patent and Trademark Office (USPTO) PharmAla has exercised i...
PharmAla reports Q3 revenue C$513,000 vs. C$135,000 last year
“PharmAla’s (MDXXF) financial position continues to improve compared to 2025, in line with the broader growth of the biotech industry,” said Nick Kadysh, CEO, PharmAla Biotech. “We were pleased to…
PharmAla Issues Q3 Financial Statements and AGM Update
PharmAla files Q3 financial statements, highlighting improved financial performance compared to 2025, and provides an update on motions passed at their AGM
Pharmala Biotech Holdings Registration statement: Q3 2026
Pharmala Biotech Holdings filed a registration statement on July 29, 2026, providing details about a securities offering with the SEC.
Pharmala Biotech Holdings Registration statement: Q3 2026
Pharmala Biotech Holdings filed a registration statement on July 29, 2026, providing details about a securities offering with the SEC.
Pharmala Biotech Holdings Earnings release: Q3 2026
Pharmala Biotech Holdings released its Q3 2026 earnings on July 29, 2026, summarizing the period's financial results.
PharmAla enters up to $100M ALA-002 license pact with Jupiter Neurosciences
PharmAla (MDXXF) announced that it has entered into a definitive license agreement on July 20 with Jupiter Neurosciences (JUNS), under which PharmAla has granted Jupiter an exclusive, perpetual, royal...
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
PharmAla signs definitive agreement with Jupiter Neurosciences to out-license their patented ALA-002 molecule, securing up-front and development payments.
PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset
PharmAla announces the completion of manufacture of ALA-002 drug substance, as well as a full operational update on the LaNeo Gen 2 patented drug family.
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002 to Jupiter Neurosciences in a Transaction Valued at Over $100 Million USD
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) (“PharmAla” or the “Company”), a leader in the research, development, and manufacturing of clinical-...
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) (“PharmAla” or the “Company”), a biotechnology company focused on the research, development, and ma...
PharmAla Issues Q2 Financial Statements and Grants Options
TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and man...
Pharmala Biotech Holdings Earnings release: Q2 2026
Pharmala Biotech Holdings released its Q2 2026 earnings on April 21, 2026, summarizing the period's financial results.
Pharmala Biotech Holdings Registration statement: Q2 2026
Pharmala Biotech Holdings filed a registration statement on April 21, 2026, providing details about a securities offering with the SEC.
Pharmala Biotech Holdings Registration statement: Q2 2026
Pharmala Biotech Holdings filed a registration statement on April 21, 2026, providing details about a securities offering with the SEC.
PharmAla positioned to supply U.S. expanded access pathway for MDMA
PharmAla (MDXXF) Biotech responded to the Executive Order signed on April 18, 2026 by the President of the United States, which directs the U.S. Food and Drug Administration and the…
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order
PharmAla is positioned to supply the US market with MDMA, and is advancing its next-generation patented safer MDMA product for human dosing this year.
Cortexa Advances Commercialisation of MDMA Supply in Australia
MELBOURNE, Australia, March 23, 2026 (GLOBE NEWSWIRE) -- Cortexa (Cortexa or the Company), a leading psychedelic medicines supplier, reaffirms its market leading position in FY2026 for MDMA (3,4-methy...
PharmAla signs supply, data agreement with Nautilus Sanctuary
PharmAla (MDXXF) Biotech executed a Supply & Data Agreement with Nautilus Sanctuary of Brooklyn, New York, for the provision of MDMA for use in a Phase 2 clinical trial in…
PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders
TORONTO, March 03, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and...
PharmAla signs drug donation agreement with Spaulding Rehabilitation
PharmAla (MDXXF) Biotech executed an agreement with Spaulding Rehabilitation for the provision of MDMA for use in a clinical trial investigating MDMA-assisted therapy for the treatment of fibromyalgia...
PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia
TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and ...
PharmAla to supply Amsterdam UMC with LaNeo MDMA
PharmAla (MDXXF) Biotech executed a binding supply agreement with Amsterdam University Medical Center in the Netherlands for the provision of LaNeo 40mg MDMA capsules for use in a proposed clinical…